(Albany, US), October 20, 2026 – DelveInsight’s “Neurotrophic Keratopathy Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of Neurotrophic Keratopathy, historical and forecasted epidemiology, as well as the Neurotrophic Keratopathy market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Explore the intricate details of the Neurotrophic Keratopathy Market Report @ Neurotrophic Keratopathy Treatment Market Size
Key Takeaways from the Neurotrophic Keratopathy Market Report
The market size of neurotrophic keratitis in the 7MM was ~USD 870 million in 2024 and is anticipated to increase during the forecast period from 2025 to 2034.
The neurotrophic keratitis market is projected to grow at a significant CAGR by 2034 in leading countries (US, EU4, UK, and Japan).
The US market size of neurotrophic keratitis was nearly USD 850 million in 2024, accounting for approximately 98% of the total 7MM market size.
According to DelveInsight’s research, there were approximately 140,000 prevalent cases of neurotrophic keratitis across the 7MM in 2024, which are expected to increase by 2034.
In 2024, the prevalence of neurotrophic keratitis was highest in the US among the 7MM, accounting for nearly 67,000 cases.
In 2024, France accounted for the largest share of the EU4 and the UK market for neurotrophic keratitis, representing nearly 30%, whereas Germany registered the smallest share at about 10%.
Neurotrophic keratitis results in impaired corneal healing, putting patients at risk for corneal ulcers, scarring, and vision loss. The chronic nature of the disease and the limited availability of effective treatments create a significant unmet need, prompting a focus on regenerative therapies and targeted interventions.
The leading Neurotrophic Keratopathy Companies include Dompé Farmaceutici, BRIM Biotechnology, RegeneRx Biopharmaceuticals, RECORDATI, Oyster Point Pharma, Oculis, Claris Biotherapeutics, and others.
Promising Neurotrophic Keratopathy Therapies include OXERVATE (Cenegermin-bkbj), BRM424, and others.
Get a Free sample for the Neurotrophic Keratopathy Market Forecast, Size & Share Analysis Report @ Neurotrophic Keratopathy Therapeutics Market
Neurotrophic Keratopathy Overview
Neurotrophic keratopathy, also known as neurotrophic keratitis or trigeminal neuropathic keratopathy, is a rare degenerative corneal disease characterized by symptoms such as lack of or decreased corneal sensation, corneal epithelial breakdown, and impaired healing, which increase the susceptibility of the corneal surface to injury and compromise healing. In severe cases, it can also lead to stromal melting, corneal ulceration, and even perforation.
Neurotrophic keratitis is diagnosed by careful investigation of any of the ocular and systemic conditions associated with the disease, along with quantitative measurement of the cornea’s sensitivity. The disease has three stages/severity levels: Stage I, II, and III. Timely diagnosis is very important for early-stage detection.
Neurotrophic Keratopathy Epidemiology Segmentation in the 7MM
Total Prevalent Cases of Neurotrophic Keratitis
Total Diagnosed Prevalent Cases of Neurotrophic Keratitis
Gender-Specific Diagnosed Prevalent Cases of Neurotrophic Keratitis
Severity-Specific Diagnosed Prevalent Cases of Neurotrophic Keratitis
Download the report to understand which factors are driving Neurotrophic Keratopathy Epidemiology trends @ Neurotrophic Keratopathy Prevalence
Neurotrophic Keratopathy Epidemiology Key Findings
In 2024, an estimated 60,300 people in EU4 and the UK had prevalent cases of neurotrophic keratitis, highlighting a significant regional disease burden and the growing need for earlier diagnosis, improved treatment options, and targeted strategies to prevent long-term corneal damage.
Among the EU4 and the UK, the UK had the highest diagnosed prevalent cases of neurotrophic keratitis with approximately 8,500 cases, followed by Germany with approximately 6,000 cases in 2024, whereas Spain had the lowest with approximately 3,400 cases.
In the US in 2024, diagnosed prevalent cases of neurotrophic keratitis showed a marked gender disparity, with females accounting for approximately 20,000 cases, significantly higher than the approximately 13,500 cases in males.
In Germany, prevalent cases in 2024 were notably higher among females, at approximately 3,650, compared to approximately 2,400 among males.
In Japan, prevalent cases of neurotrophic keratitis were approximately 12,350 in 2024, with numbers expected to rise further by 2034.
In 2024 in Japan, prevalent cases were predominantly Stage 3 (corneal ulcers) with approximately 2,500 cases, compared to nearly 1,950 cases in Stage 2 (persistent epithelial defects) and 1,110 cases in Stage 1 (epithelial alterations), underscoring the need for timely intervention to prevent progression.
Approved Therapies for Neurotrophic Keratopathy
Treatment of neurotrophic keratitis is mainly targeted toward the specific symptoms of the respective patients. OXERVATE (Cenegermin-bkbj), developed by Dompé Farmaceutici, is the first medication approved by the US FDA for the treatment of neurotrophic keratitis. Its main ingredient, cenegermin, is a structurally identical recombinant form of human Nerve Growth Factor (NGF), supplied as a clear, colorless sterile solution for topical ophthalmic use. For patients with worsening disease, a surgical approach is adopted, and amniotic membrane placement may be considered for patients with corneal ulcerations that are not healing over time or for patients with a severely affected cornea.
In July 2020, Dompé Farmaceutici partnered with Tanner Pharma Group, making them the exclusive distributor of OXERVATE (cenegermin) in select countries.
In March 2019, Dompé Farmaceutici announced that the NORD had awarded them the 2019 Industry Innovation Award for OXERVATE.
In August 2018, the US FDA approved OXERVATE (cenegermin) for the treatment of neurotrophic keratitis.
In May 2017, the EMA granted a positive opinion recommending OXERVATE for marketing authorization to treat moderate to severe neurotrophic keratitis.
Neurotrophic Keratopathy Pipeline Analysis
BRM424 is a regenerative peptide with neurotrophic properties, and its mechanism of action is based on its ability to stimulate limbal stem cell regeneration. Preclinical studies demonstrate that BRM424 stimulates the proliferation and differentiation of corneal limbal stem cells to effectively regenerate healthy limbus after extensive limbal layer removal and to speed up the cornea repair process. This direct activation of limbal stem cells can lead to fast and effective corneal healing. BRM424 is a topical therapy currently in Phase II development.
In December 2022, the US FDA granted an Orphan Drug Designation (ODD) for BRM424 in the treatment of neurotrophic keratitis.
In April 2023, BRIM Biotechnology submitted an Investigational New Drug (IND) application for BRM424 for a Phase II trial for the treatment of neurotrophic keratitis.
In September 2023, BRIM Biotechnology raised approximately USD 45.8 million by issuing 22,500 shares at NTD 65 (USD 2.03) each, with full payment received four days early. The funds will advance pipeline development, including the Phase III trial of BRM421 for dry eye disease and Phase II enrollment of BRM424 for neurotrophic keratitis.
Discover more about therapies set to grab Major Neurotrophic Keratopathy Market Share @ Neurotrophic Keratopathy Market Drivers and Barriers
Neurotrophic Keratopathy Market Outlook
Managing neurotrophic keratitis requires a comprehensive approach focused on treating the underlying cause and maintaining corneal integrity. Therapeutic strategies vary by severity, ranging from lubricants and anti-inflammatory agents to advanced interventions such as eyelid closure, punctal plugs, and surgical procedures, which, while effective, may temporarily affect vision. Emerging biological therapies, including cenegermin, biopolymers, Coenzyme Q10, and antisense oligonucleotides, offer promising potential to directly address corneal neuropathy and improve long-term outcomes.
The neurotrophic keratitis market is poised for transformation with the anticipated introduction of the emerging therapy BRM424. Its approval could significantly influence market dynamics, although the ultimate success of the therapy remains uncertain. Upcoming therapies, including BRM424, are expected to drive market expansion, with the total market size expected to change in the upcoming years. The outlook is also evolving toward targeted, cornea-protective strategies, supported by innovations in drug delivery (topical formulations, sustained-release eye drops, and bioengineered corneal grafts) and advances in diagnostic tools such as high-resolution corneal imaging, in vivo confocal microscopy, and biomarker-based assessments.
Neurotrophic Keratopathy Treatment Landscape
The key aim of neurotrophic keratitis treatment is to prevent the progression of corneal damage, which can be achieved through early diagnosis, severity-based treatment, and continuous and careful monitoring of the patient’s condition. Topical eye medications are advised to be stopped immediately. Stage I focuses on preventing epithelial damage through preservative-free lubricants and managing associated ocular surface disorders. Stage II targets the healing of persistent epithelial defects and the prevention of corneal ulcers, using antibiotics, therapeutic contact lenses, and careful steroid administration. Stage III addresses severe corneal damage and interstitial melts with advanced surgical interventions and, when appropriate, the use of collagenase inhibitors. Other than pharmacological treatment options, therapeutic corneal or scleral contact lenses are also used. Key factors driving the market include a rising patient pool, supported by increasing awareness, improved diagnosis, and the aging population, along with growing focus on regenerative therapies.
To know more about Neurotrophic Keratopathy Companies working in the treatment market, visit @ Neurotrophic Keratopathy Market Access and Reimbursement
Scope of the Neurotrophic Keratopathy Market Report
Coverage- 7MM
Study Period- 2020-2034
Forecast Period- 2025-2034
Neurotrophic Keratopathy Companies- Dompé Farmaceutici, BRIM Biotechnology, RegeneRx Biopharmaceuticals, RECORDATI, Oyster Point Pharma, Oculis, Claris Biotherapeutics, and others.
Neurotrophic Keratopathy Therapies- OXERVATE (Cenegermin-bkbj), BRM424, and others.
Neurotrophic Keratopathy Market Dynamics: Neurotrophic Keratopathy market drivers and market barriers
Neurotrophic Keratopathy Competitive Intelligence Analysis: SWOT Analysis, Attribute Analysis
Neurotrophic Keratopathy Unmet Needs, KOL Views, Reimbursement
Table of Contents
Key Insights
Report Introduction
Neurotrophic Keratopathy Market Overview at a Glance
Executive Summary of Neurotrophic Keratopathy
Key Events
Neurotrophic Keratopathy: Disease Background and Overview
Epidemiology and Patient Population
Japan
Patient Journey
Marketed Therapy
Emerging Therapies
Neurotrophic Keratopathy: Seven Major Market Analysis
KOL Views
SWOT Analysis
Unmet Needs
Market Access and Reimbursement
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Abhishek kumarEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/sample-request/neurotrophic-keratopathy-market
